We used a recently developed system for real‐time quantitative polymerase chain reaction
(PCR) to determine residual disease in patients with chronic myeloid leukaemia. The …

Increasing numbers of patients with chronic myeloid leukaemia (CML) treated with tyrosine
kinase inhibitors achieve undetectable levels of BCR‐ABL mRNA using sensitive …

We sought evidence of BCR/ABL transcripts in the peripheral blood of nine CML patients in
complete clinical and cytogenetic remission after treatment by bone marrow transplantation …

We have developed a rapid real‐time quantitative PCR method for measuring BCR‐ABL
mRNA levels in peripheral blood in chronic myeloid leukaemia (CML). The technique was …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

The principle aim of residual disease analysis in patients with chronic myeloid leukaemia
(CML) is to gauge patient response to treatment and, in patients after allogeneic BMT, to …

We describe the methodology and application of the polymerase chain reaction to detect
BCR-ABL mRNA as a marker for CML cells. The technique is highly sensitive enabling the …

Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL
fusion transcripts in CML but they are hardly reproducible. In this work, we have developed …

BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

Real-time quantitative reverse-transcription polymerase chain reaction (RQ-PCR) methods
for the quantitation of BCR-ABL mRNA in the blood of patients with chronic myeloid …